Trial Profile
A phase II study of an oral nucleoside antitumor agent consisting trifluridine and tipiracil hydrochloride for previously fluoropyrimidine-treated elderly patients with unresectable or recurrent colorectal cancer (T-CORE1401)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms T-CORE1401
- 12 Jun 2018 Status changed from active, no longer recruiting to completed, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Primary endpoint (Progression-free survival (PFS)) has been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results (n=30) assessing efficacy of trifluridine/tipiracil in elderly patients with advanced colorectal cancer, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.